Icagen shares spike after Pfizer re-ups on pain; S*Bio gets $5M investment; Bad year for IPOs

@FierceBiotech: Novartis wins landmark approval for oral MS drug. Article | Follow @FierceBiotech

 @JohnCFierce: Lundbeck is cutting its R&D staff while shifting to more collaborations on brain diseases. Article | Follow @JohnCFierce

> Icagen will get $5 million from Pfizer after the two companies agreed to extend their pain pact by a year. This is the second extension for Icagen, which remains eligible for $359 million in milestones. Investors seemed to like the sound of that and bid up Icagen's share (ICGND) price by 18 percent this morning. Icagen release | Report

> Singapore-based S*BIO Pte Ltd announced a $5 million investment by Mitsui Ventures. The investment follows the recent completion of patient enrolment for S*BIO's Phase II clinical trials with its orally-active JAK2 inhibitor, SB1518. S*BIO release

> AstraZeneca's experimental cancer drug vandetanib has been simultaneously filed for review in Europe and the U.S. And the FDA says it will give the therapy a priority review. Story

> Ziopharm has won orphan drug status for Zinapar, an experimental drug for aggressive lymphomas. Report

And Finally... The overall state of IPOs in the U.S. remains woeful. Bloomberg found that investors lost money on 61 percent of this year's offerings while 68 percent were forced to cut their prospective price. Story

Suggested Articles

Frontage is Growing to Meet All Your Needs! Click Here to Learn About the Next Generation of Frontage.

Cara Care, a digital health startup focused on digestive diseases, raised $7 million to bring its mobile app to more patients in the U.S.

Investors looked past the headline success of Sci-B-Vac, zeroed in on the failure to achieve a secondary objective and sent VBI’s stock down 66%.